16,16-Dimethyl prostaglandin E2 reduces bile acid-mediated intestinal vascular injury in rats.
To examine the effects of prostaglandin on bile acid-mediated intestinal vascular injury, male rats were given 50 mg/kg of fluorescein isothiocyanate (FITC)-stained dextran 70 or 25 mg/kg of Evans Blue intravenously. Before intestinal injury with 45-minute perfusion of 5 mmol/L chenodeoxycholic acid, rats received 16,16-dimethyl prostaglandin E2 (5 micrograms/kg intravenously or 0.5 micrograms/mL or in the perfusate for 15 minutes or vehicle). FITC-dextran clearance from the blood to the intestinal lumen and tissue Evans Blue content were used as measures of intestinal vascular injury. Morphological mucosal injury was assessed by transmission electron microscopy and quantitative histological analysis. Chenodeoxycholic acid perfusion caused villous denudation and shortening of and ultrastructural damage to villous venules. Functional vascular injury was evidenced by a 10-fold increase in the rate of FITC-dextran blood-to-lumen clearance and a 3-4-fold increase in tissue Evans Blue content. Pretreatment with either intravenous or intraluminal 16,16-dimethyl prostaglandin E2 reduced FITC-dextran clearance by 70%-80% and tissue Evans Blue content by 50%. However, only luminal prostaglandin reduced superficial mucosal morphological injury, possibly because of differences in the local concentrations of 16,16-dimethyl prostaglandin E2 or chenodeoxycholic acid or because of superficial mucosal protection and injury being, at least in part, independent of mucosal microvascular injury and protection.
Department of Medicine, Department of Veterans Affairs Medical Center, Long Beach, California.
R A
RA
Erickson
K
K
Chang
E
E
Lifrak
N
N
Rivera
J
J
Stachura
D015064:16,16-Dimethylprostaglandin E2 / Q000494:pharmacology*; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D001834:Body Water / Q000378:metabolism; D002199:Capillary Permeability / Q000187:drug effects*; D002635:Chenodeoxycholic Acid / Q000633:toxicity*; D003911:Dextrans / Q000493:pharmacokinetics; D005070:Evans Blue / Q000493:pharmacokinetics; D016650:Fluorescein-5-isothiocyanate / Q000493:pharmacokinetics / Q000031:analogs & derivatives; D007413:Intestinal Mucosa / Q000098:blood supply / Q000187:drug effects* / Q000473:pathology; D051381:Rats
D003911:Dextrans; C015219:fluorescein isothiocyanate dextran; D002635:Chenodeoxycholic Acid; D005070:Evans Blue; D016650:Fluorescein-5-isothiocyanate; D015064:16,16-Dimethylprostaglandin E2